Autres langues Clover Biopharmaceuticals, Ltd.

Actions

2197

KYG2280A1076

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:22 29/04/2024			Varia. 5j.	Varia. 1 janv.
0,345 ^HKD	-4,17%		+6,15%	-44,35%

08/04	Le candidat vaccin de Clover Biopharmaceuticals contre le virus respiratoire syncytial (VRS) se révèle prometteur lors d'un essai préliminaire	MT
08/04	Clover Biopharmaceuticals, Ltd. Clover Biopharmaceuticals Ltd. annonce des résultats préliminaires positifs pour le vaccin bivalent contre le VRS SCB-1019 dans la cohorte initiale de jeunes adultes.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding	12/04
Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial	08/04
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort	08/04
Clover Biopharmaceuticals, Ltd. Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 In Initial Young Adult Cohort	08/04
Clover Biopharmaceuticals, Ltd. announced that it expects to receive $0.320713 million in funding	02/04
Clover Biopharmaceuticals Trims Losses in 2023	27/03
Clover Biopharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Sinovac Halts Production of COVID-19 Vaccine as Demand Wanes	12/01
Clover Announces Positive Phase ? Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)	29/12
Clover Biopharmaceuticals Publishes Positive Results from SCB-219M Clinical Trial	29/12
Clover Biopharmaceuticals, Ltd. Announces Positive Phase I Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia	29/12
Clover Biopharmaceuticals Completes Patient Enrollment for Australia Phase 1 Trial; Shares Fall 5%	13/12
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate	13/12
Clover Biopharmaceuticals, Ltd. Initiates Phase Clinical Trial for RSV Vaccine Candidate	13/12
Clover Biopharmaceuticals Completes Submission of Application for Seasonal Flu Vaccine in Brazil	07/11
Clover Biopharmaceuticals, Ltd. Completes Biologic License Application for Its Seasonal Influenza Vaccine in Brazil	07/11
Clover Biopharmaceuticals Rolls Out Quadrivalent Seasonal Influenza Vaccine in Mainland China	12/09/23
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China	12/09/23
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China	12/09/23
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China	12/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Clover Biopharmaceuticals, Ltd.

Actions

2197

KYG2280A1076

Autres langues

Filtres